Updated 2026 consensus recommendations from the American Diabetes Association and European Association for the Study of Diabetes call for earlier, more comprehensive management of type 2 diabetes (T2D), emphasizing organ protection and prevention of long-term complications beyond glycemic control. The guidance advocates considering sodium-glucose cotransporter-2 inhibitors and/or glucagon-like peptide-1 (GLP-1)-based therapies early, potentially at diagnosis, based on individual cardiovascular, kidney, and metabolic risks. Earlier combination therapy may be appropriate for patients with cardiovascular disease, chronic kidney disease, or heart failure, regardless of hemoglobin A1c levels. Updated recommendations also address metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatohepatitis, obesity, obstructive sleep apnea, and atrial arrhythmias. For patients with obesity and heart failure with preserved ejection fraction, semaglutide or tirzepatide is recommended, while GLP-1-based therapies and pioglitazone are among the treatment options discussed for MASH.

The updated guidance reinforces the importance of individualized medication selection, early assessment of cardiorenal risk, and multidisciplinary diabetes management. Beyond pharmacotherapy, recommendations emphasize medical nutrition therapy, diabetes self-management education and support, and the “5 S’s” of physical activity and wellness: standing more, walking 8,000 to 10,000 steps daily, sweating through at least 150 minutes of moderate-to-vigorous activity weekly, strengthening muscles 2 to 3 days weekly, and sleeping 7 to 8 hours nightly. However, medication affordability and access remain significant barriers to implementation. The article also highlights findings from the SMARTEST trial, in which dapagliflozin did not demonstrate superior cardiovascular, microvascular, or mortality outcomes compared with metformin in patients with recently diagnosed, uncomplicated T2D. These findings underscore the continued role of metformin and the need to tailor early treatment decisions to individual risk profiles, comorbidities, and access to care.

Reference: Tucker ME. ADA/EASD call for early, holistic type 2 diabetes care. Medscape Medical News. Published October 7, 2026. Accessed October 14, 2026. https://www.medscape.com/viewarticle/ada-easd-call-early-holistic-type-2-diabetes-care-2026a10011iv

Investigators of a retrospective study of 594 adults across two primary care clinics found that delays in documenting type 2 diabetes (T2D) diagnoses were associated with gaps between appointments and potentially missed diagnostic opportunities during follow-up visits. Researchers analyzed electronic health record (EHR) data from 2017 through 2023, measuring the time between an initial diabetes-range hemoglobin A1c (≥6.5%) result and a formally documented T2D diagnosis. Among patients whose diagnosis was not documented on the same day as the elevated result, the median time to diagnosis was 1.6 months at one clinic and 2.0 months at the other. At six months, 20.8% and 28.0% of patients, respectively, remained without an EHR-documented diagnosis. Longer intervals between primary care visits were significantly associated with slower diagnostic documentation (hazard ratio, 0.63; 95% CI, 0.60-0.67), while the adjusted difference between clinics was not statistically significant.

The findings highlight the importance of timely follow-up, confirmatory testing, and reliable documentation after abnormal glycemic results. The likelihood of a first documented diagnosis was concentrated in the earlier follow-up visits, with estimated conditional probabilities of 27.6%, 33.3%, and 31.4% at visits one, two, and three, respectively. A separate simulation suggested that 9.69% of patients could remain in a laboratory-defined T2D state without a corresponding diagnosis code after one year, indicating possible gaps in diagnostic confirmation or documentation. Because the study included only patients who ultimately received a T2D diagnosis, its findings cannot establish the prevalence of undiagnosed diabetes across the broader primary care population. Nevertheless, the researchers emphasized systematic follow-up protocols, care navigation, and digital reminders as potential strategies to improve diagnostic timeliness and support earlier intervention.

Reference: Lotfibagha P, Miller K, Gallagher WJ, et al. A time-to-event analysis to conceptualize and predict delay in type 2 diabetes diagnosis in primary care. BMC Prim Care. 2026. doi: 10.1186/s12875-026-03529-6.

Authors of a systematic review and network meta-analysis of 51 randomized controlled trials involving 4,129 adults with prediabetes examined whether six nonpharmacological traditional Chinese medicine interventions could improve glycemic control, body mass index (BMI), and lipid levels compared with lifestyle interventions. The therapies included acupuncture, electroacupuncture, massage, acupoint catgut embedding, Baduanjin, and Tai Chi. Acupuncture was the only intervention associated with a statistically significant reduction in hemoglobin A1c compared with lifestyle interventions (mean difference, -0.80 percentage points; 95% CI, -1.27 to -0.32). Massage ranked highest for reducing fasting plasma glucose and 2-hour postprandial glucose, with mean differences of -1.49 and -1.80 mmol/L, respectively, compared with lifestyle interventions. Electroacupuncture ranked highest for BMI reduction, while Baduanjin demonstrated significant improvements in fasting glucose, postprandial glucose, total cholesterol, and triglycerides. However, the analysis did not establish that any single therapy was consistently superior across all outcomes.

The findings suggest that selected traditional Chinese medicine interventions may offer additional options for patients interested in nonpharmacological approaches to prediabetes management. However, the evidence remains preliminary. Most trials had methodological limitations, substantial heterogeneity was observed across all outcomes, and the lack of direct comparisons between therapies limits confidence in the rankings. Safety reporting was also incomplete, with only 12 of 51 trials documenting adverse events; acupoint catgut embedding accounted for most reported reactions. Importantly, the analysis did not establish whether these interventions reduce progression to type 2 diabetes or provide additional benefits when combined with standard medical management. Lifestyle modification, including regular physical activity, dietary improvements, and weight management, remains the foundation of prediabetes care. Clinicians should discuss the uncertain benefits and potential risks of complementary interventions with interested patients while emphasizing evidence-based prevention strategies and continued glycemic monitoring.

Reference: Qi X, Wang T, Liao L. Non-pharmacological therapies of traditional Chinese medicine in prediabetes: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2026 Aug 27;17:1907358. doi: 10.3389/fendo.2026.1907358.